Prot #17-448: A Phase 2 Study of Pembrolizumab In Patients with Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas

Project: Research project

Project Details

StatusFinished
Effective start/end date2/5/20 → 2/5/23

Funding

  • Dana-Farber/Partners CancerCare, Inc. (Prot #17-448)